IRYCIS
New biomarkers to predict secundary autoimmunity before the treatment with alemtuzumab in MS
Biomarkers
Autoimmune & Inflammation
Central Nervous System
New method to determine the probability to develop a secondary autoimmune disease before the treatment with alemtuzumab in patients with Multiple Sclerosis
5Ready to Market,
4Register,
3Clinical validation,
2Preclinical Validation,
1R+D
Spain